“The Pink Sheet” regularly provides commentary and perspective on key business deals. Here’s a summary of the most noteworthy transactions taking place between Jan. 16-23.
Deal Watch: NASH Space Heats Up With Tobira/Regado Reverse-Merger
Roche buys out French biotech Trophos, with plans to continue developing its failed ALS candidate in spinal muscular atrophy. Meanwhile, the ramifications from last year’s complex Novartis/GSK tie-up continue, as Novartis transfers a Phase III BRAF inhibitor to Array a month after returning a MEK inhibitor to its former partner.
More from Archive
More from Pink Sheet
Canada’s health products regulator is inviting feedback on a range of new and revised guidelines and regulatory tools that explain how drug and device companies will be able to comply with significant changes proposed to its shortages framework.
The European Medicines Agency says it will take appropriate measures to update the Ozempic’s package leaflet if new evidence arises.
Doxecitine/doxribtimine, UCB’s investigational orphan drug for pediatric and adult patients with thymidine kinase 2 deficiency, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.